X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
Frequently asked questions
What sector does X4 Pharmaceuticals Inc (XFOR) operate in?
X4 Pharmaceuticals Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is X4 Pharmaceuticals Inc (XFOR) current stock price?
As of the latest data, X4 Pharmaceuticals Inc stock price is $3.25, with a previous close of $3.24. X4 Pharmaceuticals Inc gained $0.01 in the last trading session, representing a 0.31% increase.
What is X4 Pharmaceuticals Inc (XFOR) current market capitalization?
X4 Pharmaceuticals Inc market cap is approximately 322.23 million.
What is X4 Pharmaceuticals Inc (XFOR) Earnings Per Share (EPS)?
The trailing EPS is $1.45, and the forward EPS is -$0.77.
What is X4 Pharmaceuticals Inc (XFOR) Price-to-Earnings (P/E) ratio?
X4 Pharmaceuticals Inc current P/E ratio is 2.24.
What is X4 Pharmaceuticals Inc (XFOR) EBITDA?
X4 Pharmaceuticals Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -12.77 million.
Does X4 Pharmaceuticals Inc (XFOR) pay dividends?
No. X4 Pharmaceuticals Inc does not pay a dividend.
How did X4 Pharmaceuticals Inc (XFOR) perform in its most recent earnings report?
In the last report (June 30, 2026), X4 Pharmaceuticals Inc posted an EPS surprise of 31.58% and a revenue surprise of 263.88%.
When is X4 Pharmaceuticals Inc (XFOR) next earnings report?
X4 Pharmaceuticals Inc is expected to release its next earnings report on September 30, 2026.
What is X4 Pharmaceuticals Inc (XFOR) beta (volatility) score?
X4 Pharmaceuticals Inc has a beta of 0.395, indicating lower volatility than the overall market.
